

ADC Therapeutics SA (ADCT)

FEBRUARY 19, 2025 | MISSOURI & TEXAS
FEBRUARY 20, 2025 | CHICAGO & MILWAUKEE



Management

Ameet Mallik
CEO

Pepe Carmona
CFO

Marcy Graham
IRO

Roadshow Host

Sudan Loganathan, PhD
Managing Director
Biotechnology
(212) 891-1762
sudan.loganathan@stephens.com

Space will be limited. Meeting times and itinerary subject to change. To join the event or to obtain more information, please contact your Stephens sales representative.

About ADC Therapeutics SA

ADC Therapeutics (NYSE: ADCT) is a commercial-stage company that is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received FDA accelerated approval and European conditional approval for the treatment of r/r DLBCL after 2L+ systemic therapy. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London and New Jersey.